Carna Biosciences, Inc. 4572.T Stock
Carna Biosciences, Inc. Price Chart
Carna Biosciences, Inc. 4572.T Financial and Trading Overview
| Carna Biosciences, Inc. stock price | 459 JPY |
| Previous Close | 869 JPY |
| Open | 877 JPY |
| Bid | 910 JPY x 0 |
| Ask | 917 JPY x 0 |
| Day's Range | 873 - 917 JPY |
| 52 Week Range | 447 - 958 JPY |
| Volume | 771.9K JPY |
| Avg. Volume | 898.8K JPY |
| Market Cap | 15.62B JPY |
| Beta (5Y Monthly) | 1.46475 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -68.64 JPY |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
4572.T Valuation Measures
| Enterprise Value | 11.5B JPY |
| Trailing P/E | N/A |
| Forward P/E | 8.127773 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 14.759634 |
| Price/Book (mrq) | 3.5386195 |
| Enterprise Value/Revenue | 10.868 |
| Enterprise Value/EBITDA | -6.607 |
Trading Information
Carna Biosciences, Inc. Stock Price History
| Beta (5Y Monthly) | 1.46475 |
| 52-Week Change | 2.59% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 958 JPY |
| 52 Week Low | 447 JPY |
| 50-Day Moving Average | 721.54 JPY |
| 200-Day Moving Average | 695.52 JPY |
4572.T Share Statistics
| Avg. Volume (3 month) | 898.8K JPY |
| Avg. Daily Volume (10-Days) | 669.88K JPY |
| Shares Outstanding | 17.05M |
| Float | 14.91M |
| Short Ratio | N/A |
| % Held by Insiders | 6.98% |
| % Held by Institutions | 14.49% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 100:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -175.14% |
| Operating Margin (ttm) | -167.95% |
| Gross Margin | 83.26% |
| EBITDA Margin | -164.50% |
Management Effectiveness
| Return on Assets (ttm) | -21.56% |
| Return on Equity (ttm) | -41.47% |
Income Statement
| Revenue (ttm) | 1.06B JPY |
| Revenue Per Share (ttm) | 74.43 JPY |
| Quarterly Revenue Growth (yoy) | -59.19% |
| Gross Profit (ttm) | 1.22B JPY |
| EBITDA | -1740499968 JPY |
| Net Income Avi to Common (ttm) | -1852999936 JPY |
| Diluted EPS (ttm) | -130.74 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 4.08B JPY |
| Total Cash Per Share (mrq) | 239.45 JPY |
| Total Debt (mrq) | 255M JPY |
| Total Debt/Equity (mrq) | 5.8 JPY |
| Current Ratio (mrq) | 12.324 |
| Book Value Per Share (mrq) | 258.858 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Carna Biosciences, Inc.
| Country | Japan |
| State | N/A |
| City | Kobe |
| Address | BMA, 1-5-5 Minatojima-Minamimachi |
| ZIP | 650-0047 |
| Phone | 81 78 302 7039 |
| Website | https://www.carnabio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 65 |
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, and tyrosine kinase cell-based assay services. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials. The company has collaborations with Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals. Carna Biosciences, Inc. was incorporated in 2003 and is based in Kobe, Japan.
Q&A For Carna Biosciences, Inc. Stock
What is a current 4572.T stock price?
Carna Biosciences, Inc. 4572.T stock price today per share is 459 JPY.
How to purchase Carna Biosciences, Inc. stock?
You can buy 4572.T shares on the Tokyo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Carna Biosciences, Inc.?
The stock symbol or ticker of Carna Biosciences, Inc. is 4572.T.
Which industry does the Carna Biosciences, Inc. company belong to?
The Carna Biosciences, Inc. industry is Biotechnology.
How many shares does Carna Biosciences, Inc. have in circulation?
The max supply of Carna Biosciences, Inc. shares is 17.14M.
What is Carna Biosciences, Inc. Price to Earnings Ratio (PE Ratio)?
Carna Biosciences, Inc. PE Ratio is now.
What was Carna Biosciences, Inc. earnings per share over the trailing 12 months (TTM)?
Carna Biosciences, Inc. EPS is -68.64 JPY over the trailing 12 months.
Which sector does the Carna Biosciences, Inc. company belong to?
The Carna Biosciences, Inc. sector is Healthcare.